Premium
Challenges and Opportunities With Oncology Drug Development in China
Author(s) -
Bajaj Gaurav,
Gupta Manish,
Wang HweiGene Heidi,
Barrett Jeffrey S.,
Tan Matthew,
Rupalla Katrin,
Bertz Richard,
Sheng Jennifer
Publication year - 2019
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1017
Subject(s) - china , pace , drug development , cancer drugs , medicine , public health , drug approval , oncology , clinical oncology , cancer treatment , family medicine , drug , cancer , economic growth , environmental health , political science , pharmacology , geography , nursing , economics , geodesy , law
Cancer is a growing public health problem in China. Despite the high unmet medical need of patients with cancer in China, oncology drug approvals have historically lagged behind those in the West, mainly the United States and Europe. China is currently undertaking regulatory reforms at a fast pace in order to mitigate this lag.